Subcutaneous delivery of FGF21 mRNA therapy reverses obesity, insulin resistance, and hepatic steatosis in diet-induced obese mice

• Main Authors: Stefano Bartesaghi (Author), Kristina Wallenius (Author), Daniel Hovdal (Author), Mathias Liljeblad (Author), Simonetta Wallin (Author), Niek Dekker (Author), Louise Barlind (Author), Nigel Davies (Author), Frank Seeliger (Author), Maria Sörhede Winzell (Author), Sima Patel (Author), Matt Theisen (Author), Luis Brito (Author), Nils Bergenhem (Author), Shalini Andersson (Author), Xiao-Rong Peng (Author)
• Format: Book
• Published: Elsevier, 2022-06-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Fibroblast growth factor 21 (FGF21) is a promising therapeutic agent for treatment of type 2 diabetes (T2D) and non-alcoholic steatohepatitis (NASH). We show that therapeutic levels of FGF21 were achieved following subcutaneous (s.c.) administration of mRNA encoding human FGF21 proteins. The efficac...